Sunovion Pharmaceuticals Inc will present eight posters featuring data from its robust portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2018 (ATS 2018), taking place May 18-23, 2018, in San Diego, California. New data analyses include three posters reporting effects of Seebri Neohaler (glycopyrrolate) Inhalation Powder and Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder on lung function and patient-reported outcomes.

“Sunovion is committed to research that advances clinical understanding and treatment options for COPD, which affects millions of Americans,” said Thomas H. Goodin, PhD, Senior Director of Clinical Development at Sunovion. “We look forward to presenting this data at ATS, reinforcing our focus on providing a portfolio of innovative treatment options to support individual patient needs.”

Seebri Neohaler is a long-acting muscarinic antagonist (LAMA). Utibron Neohaler is a combination long-acting beta2 agonist (indacaterol) (LABA) and LAMA (glycopyrrolate). Both therapies are approved in the U.S. for the twice-daily, long-term maintenance treatment of airflow obstruction in people with COPD, including chronic bronchitis and/or emphysema.

Sunovion presentations at ATS 2018 include:

Seebri Neohaler:

  • Poster #8868: Lung Function and Patient-Reported Outcomes Response to Glycopyrrolate (Seebri Neohaler) in COPD Patients by Reversibility: Pooled Analysis of the GEM1 and GEM2 Studies (Sunday, May 20, 9:15 a.m. – 4:15 p.m. PDT, Area E, Hall A-B2)

Utibron Neohaler:

  • Poster #8841: Lung Function and Patient-Reported Outcomes Response to Indacaterol/Glycopyrrolate (Utibron Neohaler) in COPD Patients by Reversibility: Pooled Analysis of the FLIGHT1 and FLIGHT2 Studies (Sunday, May 20, 9:15 a.m. – 4:15 p.m. PDT, Area E, Hall A-B2)
  • Poster #8861: Lung Function and Patient-Reported Outcomes Response to Indacaterol/Glycopyrrolate (Utibron Neohaler) in COPD Patients by Smoking Status: Pooled Analysis of the FLIGHT1 and FLIGHT2 Studies (Sunday, May 20, 9:15 a.m. – 4:15 p.m. PDT, Area E, Hall A-B2)